Equity Research Medical Care Facilities

Should You Buy LifeStance Health Group, Inc. Stock in 2026?

By CirclFi Research Team · · Updated · 9/13 models active

According to the CirclFi Deep Alpha Valuation Engine, LifeStance Health Group, Inc. (LFST) carries a solid Quality of Company rating of 7.2/10. Trading at $13.06, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.

The short answer: 0 of 9 CirclFi valuation models project upside for LifeStance Health Group, Inc. (LFST) at $13.06 — the model consensus leans bearish, with a Quality Score of 7.2/10 and Value-Trap risk of 18/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 9 of 9 models suggest overvaluation — majority bearish
  • Quality Score: 7.2/10 — Strong — above-average quality
  • Value Trap Risk: 18/100 — Minimal — healthy fundamentals
  • Fair Value Range: $0.66 – $10.69 (1520% spread)

Bullish Models

0 / 9

Bearish Models

9 / 9

Quality Score

7.2 /10

Strong — above-average quality

Value Trap Risk

18 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

9 /13
Active Models

Avg. confidence: 41%

What Is the Investment Case for LifeStance Health Group, Inc. (LFST) in 2026?

What Is the Bull Case vs the Bear Case for LifeStance Health Group, Inc. (LFST)?

Bull case versus bear case for LifeStance Health Group, Inc. (LFST) at $13.06, derived from 9 active CirclFi valuation models on 2026-09-15.
Bull case Bear case — $0.66 target (-94.9%)
No active model projects meaningful upside for LFST at $13.06. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.66 (-94.9%), suggesting that the market price embeds overly optimistic growth assumptions.
According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +76.8% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.

How Does LFST Compare to Its Medical Care Facilities Peers?

JYNT The Joint Corp.
7.2
AUNA Auna SA
7.2
FMS Fresenius Medical Ca
7.3
ASTH Astrana Health, Inc.
7.1
CON Concentra Group Hold
7.5
CYH Community Health Sys
7.1
SYRA Syra Health Corp.
5.9
CMPS COMPASS Pathways plc
4.5

Valuation data pages: JYNT · AUNA · FMS · ASTH · CON · CYH · SYRA · CMPS · THC · ADUS · NHC

See full Medical Care Facilities rankings →

Which Other Stocks Score Like LFST on Quality?

Closest companies to LFST’s Quality of Company score of 7.2/10, across all industries.

Why Do CirclFi’s 9 Models Disagree on LFST?

Spread

1520%

Fair Value Range

$0.66 – $10.69

A 1520% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

Regime Cross

$10.69 (-18.1%)

Most Bearish

ML-RIV

$0.66 (-94.9%)

What Are the Biggest Risks of Buying LFST Stock?

Model Disagreement

1520% spread signals high variance in projections.

Bearish Consensus

9/9 models suggest overvaluation.

Macro/Sector Risk

Medical Care Facilities headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View LFST Data Page →

So Is LifeStance Health Group, Inc. (LFST) Worth Buying in 2026?

Our valuation engine sends a clear cautionary signal on LifeStance Health Group, Inc. at $13.06. 9/9 models flag overvaluation, median fair value sits at $2.07 (-84.2%), and the risk-reward profile appears unfavorable. Quality at 7.2/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. LifeStance Health Group, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About LFST Stock?

Should I buy LFST stock right now?

Based on CirclFi's multi-model analysis, 0 of 9 models see upside for LFST at $13.06. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in LifeStance Health Group, Inc.?

Key risks include: wide model disagreement (1520% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Care Facilities companies. Always diversify and consult a financial advisor.

How does LFST compare to its competitors?

Among Medical Care Facilities peers, LFST holds a Quality Score of 7.2/10. Comparable companies include JYNT (QOC 7.2), AUNA (QOC 7.2), FMS (QOC 7.3). The relative ranking helps investors identify whether LFST offers better fundamental quality than alternatives in the same sector.

Is LFST a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. LFST's Quality Score of 7.2/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy LFST at?

CirclFi does not provide target buy prices or price alerts. However, our 9 active models produce fair value estimates ranging from $0.66 to $10.69. At $13.06, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for LFST.

View LFST Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →